BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali Z, Tegin C, El-mallakh RS. Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opinion on Pharmacotherapy 2020;21:253-60. [DOI: 10.1080/14656566.2019.1695777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 El-Mallakh RS, Ali Z. Extra-synaptic modulation of GABAA and efficacy in bipolar disorder. Med Hypotheses 2021;147:110501. [PMID: 33515862 DOI: 10.1016/j.mehy.2021.110501] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tang SW, Tang WH, Leonard BE. Treatment-induced mood switching in affective disorders. Acta Neuropsychiatr 2022;34:55-68. [PMID: 34955101 DOI: 10.1017/neu.2021.47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Okubo R, Hasegawa T, Fukuyama K, Shiroyama T, Okada M. Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy. Front Psychiatry 2021;12:623684. [PMID: 33679481 DOI: 10.3389/fpsyt.2021.623684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Sleem A, El-Mallakh RS. Advances in the psychopharmacotherapy of bipolar disorder type I. Expert Opin Pharmacother 2021;22:1267-90. [PMID: 33612040 DOI: 10.1080/14656566.2021.1893306] [Reference Citation Analysis]